CRISPR Therapeutics AG - Company Profile
Powered by 
All the data and insights you need on CRISPR Therapeutics AG in one report.
$295
- Save hours of research time and resources with
our up-to-date CRISPR Therapeutics AG Strategy Report
- Understand CRISPR Therapeutics AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on CRISPR Therapeutics AG’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
| Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
|---|---|---|---|---|
| 15 Jun 2021 | CRISPR Therapeutics and Capsida Biotherapeutics Enter into Partnership | Partnership | - |
Capsida Biotherapeutics Inc
CRISPR Therapeutics AG |
| 06 May 2021 | Nkarta Enters into Licensing Agreement with CRISPR Therapeutics | Licensing Agreement |
Nkarta Inc
|
CRISPR Therapeutics AG |
| 11 Dec 2020 | CRISPR Therapeutics to Raise USD350 Million in Public Offering of Shares | Equity Offering | - |
CRISPR Therapeutics AG |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer